HDAC6 as a therapeutic target for HPV E7-driven cervical cancer

Abstract

Cervical cancer is one of the most prevalent malignant tumors of the female reproductive system. While its occurrence and progression is influenced by various factors, recent research has highlighted roles for histone deacetylase 6 (HDAC6) and the human papillomavirus E7 (HPV E7) protein in cervical cancer pathogenesis. HPV E7 promotes cancer cell survival and proliferation by regulating the cell cycle, inhibiting apoptosis, and integrating into the genome. Meanwhile, HDACs mediate cancer development and invasiveness by regulating key physiological processes, including cell proliferation, apoptosis, motility, epithelial–mesenchymal transition, and angiogenesis. HDAC6, specifically, contributes to cellular stress responses by deacetylating various substrate proteins and interacting with other proteins that together enhance tumor cell survival. In this review, we summarize recent advances in understanding the role of HDACs in HPV E7-induced cervical cancer, including HDAC structure and function, and HDAC6 involvement in tumor initiation and progression. We then explore the potential of HDAC6 as a therapeutic target for cervical cancer.

Keywords

Histone deacetylase 6 (HDAC6) / HPV E7 / Cervical cancer / Epigenetics / Targeted therapy / Medical and Health Sciences / Oncology and Carcinogenesis / Biological Sciences / Biochemistry and Cell Biology

References

[1] AbbassSA, HassanHA, MohamedMF, MoustafaGA, Abuo-RahmaGE-DA. Recent prospectives of anticancer histone deacetylase inhibitors. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2019, 2: 135-151

[2] Aldana-MasangkayGI, SakamotoKM. The role of HDAC6 in cancer. Journal of Biomedicine & Biotechnology, 2011, 2011875824

[3] AsmamawMD, HeA, ZhangL-R, LiuH-M, GaoY. Histone deacetylase complexes: Structure, regulation and function. Biochimica Et Biophysica Acta - Reviews on Cancer, 2024, 1879. 189150

[4] Biersack, B., Nitzsche, B. & Höpfner, M. (2024). Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization. In Seminars in cell & developmental biology (Vol. 154, pp. 286–294). Elsevier.

[5] BoyaultC, SadoulK, PabionM, KhochbinS. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene, 2007, 26: 5468-5476.

[6] Bruno, E., Buemi, M. R., Di Fiore, A., De Luca, L., Ferro, S., Angeli, A., Cirilli, R., Sadutto, D., Alterio, V., Monti, S. M., Supuran, C. T., De Simone, G., & Gitto, R. (2017). Probing Molecular Interactions between Human Carbonic Anhydrases (hCAs) and a Novel Class of Benzenesulfonamides. Journal of medicinal chemistry,60(10), 4316–4326. https://doi.org/10.1021/acs.jmedchem.7b00264

[7] CaoQ, et al. . TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells. Cancer Biotherapy & Radiopharmaceuticals, 2015, 30: 87-93.

[8] CarmonaB, MarinhoHS, MatosCL, NolascoS, SoaresH. Tubulin post-translational modifications: The elusive roles of acetylation. Biology, 2023, 12: 561.

[9] ChangP, LiH, HuH, LiY, WangT. The role of HDAC6 in autophagy and NLRP3 inflammasome. Frontiers in Immunology, 2021, 12. 763831

[10] ChenJ, et al. . The high-risk HPV oncogene E7 upregulates miR-182 expression through the TGF-β/Smad pathway in cervical cancer. Cancer Letters, 2019, 460: 75-85.

[11] d’YdewalleC, BogaertE, Van Den BoschL. HDAC 6 at the intersection of neuroprotection and neurodegeneration. Traffic, 2012, 13: 771-779.

[12] DerynckR, AkhurstRJ, BalmainA. TGF-β signaling in tumor suppression and cancer progression. Nature Genetics, 2001, 29: 117-129.

[13] Diaz-ChavezJ, Hernandez-PandoR, LambertPF, GariglioP. Down-regulation of transforming growth factor-β type II receptor (TGF-βRII) protein and mRNA expression in cervical cancer. Molecular Cancer, 2008, 7: 3.

[14] DingG, et al. . HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity. FEBS Letters, 2013, 587: 880-886.

[15] DongC, LiZ, AlvarezR, FengX-H, Goldschmidt-ClermontPJ. Microtubule binding to Smads may regulate TGFβ activity. Molecular Cell, 2000, 5: 27-34.

[16] FangJ, ZhangH, JinS. Epigenetics and cervical cancer: From pathogenesis to therapy. Tumor Biology, 2014, 35: 5083-5093.

[17] FarahME, SirotkinV, HaarerB, KakhniashviliD, AmbergDC. Diverse protective roles of the actin cytoskeleton during oxidative stress. Cytoskeleton, 2011, 68: 340-354.

[18] GallinariP, MarcoSD, JonesP, PallaoroM, SteinkühlerC. HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics. Cell Research, 2007, 17: 195-211.

[19] GeL-P, et al. . Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor. Oncogene, 2021, 40: 2323-2334.

[20] Global estimates of incidence and mortality of cervical cancer in 2020: A baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(22)00501-0/fulltext?uuid=uuid%3A5cd243c2-4f16-4e58-aaec-0f0a9b291efd

[21] GrüningerL, et al. . Sensitizing human cervical cancer cells In vitro to ionizing radiation with interferon β or γ. Radiation Research, 1999, 152: 493-498.

[22] Gu S., Liu, Y., Zhu, B., Ding, K., Yao, T. P., Chen, F., Zhan, L., Xu, P., Ehrlich, M., Liang, T., & Lin, X. (2016). Loss of α-tubulin acetylation is associated with TGF-β-induced epithelial-mesenchymal transition. Journal of Biological Chemistry,291(10), 5396–5405. https://www.jbc.org/article/S0021-9258(20)43173-4/fulltext

[23] Gu, Z., Lin, S., Yu, J., Jin, F., Zhang, Q., Xia, K., Chen, L., Li, Y., & He, B. (2024). Advances in dual-targeting inhibitors of HDAC6 for cancer treatment. European journal of medicinal chemistry, 275, 116571. https://doi.org/10.1016/j.ejmech.2024.116571

[24] GuptaS, KumarP, DasBC. HPV: Molecular pathways and targets. Current Problems in Cancer, 2018, 42: 161-174.

[25] HaiR, HeL, ShuG, YinG. Characterization of histone deacetylase mechanisms in cancer development. Frontiers in Oncology, 2021, 11. 700947

[26] HoriuchiK, MurakamiY. A new procedure for the determination of radium in water by extraction of radon and application of integral counting with a liquid scintillation counter. The International Journal of Applied Radiation and Isotopes, 1981, 32: 291-294.

[27] HuX, ChakravartySD, IvashkivLB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunological Reviews, 2008, 226: 41-56.

[28] HuangZ, LiL, ChengB, LiD. Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies. Biomedicine & Pharmacotherapy, 2024, 178. 117218

[29] IbrahimTS, et al. . Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity. Bioorganic Chemistry, 2020, 99. 103797

[30] IuzzolinoA, PellegriniFR, RotiliD, DegrassiF, TrisciuoglioD. The α-tubulin acetyltransferase ATAT1: Structure, cellular functions, and its emerging role in human diseases. Cellular and Molecular Life Sciences, 2024, 81: 193.

[31] LeeJ-Y, KongG. Roles and epigenetic regulation of epithelial–mesenchymal transition and its transcription factors in cancer initiation and progression. Cellular and Molecular Life Sciences, 2016, 73: 4643-4660.

[32] LiG, TianY, ZhuW-G. The roles of histone deacetylases and their inhibitors in cancer therapy. Frontiers in Cell and Developmental Biology, 2020, 8. 576946

[33] LiT, et al. . Histone deacetylase 6 in cancer. Journal of Hematology & Oncology, 2018, 11: 111.

[34] LiY, ShinD, KwonSH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. The FEBS Journal, 2013, 280: 775-793.

[35] LiuL, DongL, BourguetE, FairlieDP. Targeting class IIa HDACs: Insights from phenotypes and inhibitors. Current Medicinal Chemistry, 2021, 28: 8628-8672.

[36] LiuQ, et al. . Natural products as glycolytic inhibitors for cervical cancer treatment: A comprehensive review. Biomedicine & Pharmacotherapy, 2024, 175. 116708

[37] Lourenço de Freitas, N., Deberaldini, M. G., Gomes, D., Pavan, A. R., Sousa, Â., Dos Santos, J. L., & Soares, C. P. (2021). Histone deacetylase inhibitors as therapeutic interventions on cervical cancer induced by human papillomavirus. Frontiers in cell and developmental biology,8, 592868. https://doi.org/10.3389/fcell.2020.592868

[38] MeissnerJD. Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. Journal of General Virology, 1999, 80: 1725-1733.

[39] MelnickA, LichtJD. Deconstructing a disease: RAR, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood, the Journal of the American Society of Hematology, 1999, 93: 3167-3215

[40] MengF, WuG. The rejuvenated scenario of epithelial–mesenchymal transition (EMT) and cancer metastasis. Cancer and Metastasis Reviews, 2012, 31: 455-467.

[41] MoranB, DavernM, ReynoldsJV, DonlonNE, LysaghtJ. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy. Cancer Letters, 2023, 559. 216121

[42] Navakauskienė, R., Navakauskas, D., Borutinskaitė, V., & Matuzevičius, D. (2021). Chromatin remodeling during leukemia cell proliferation and differentiation. In Epigenetics and proteomics of leukemia (pp. 67–122). Springer International Publishing. https://doi.org/10.1007/978-3-030-68708-3_3

[43] PalazzoA, AckermanB, GundersenGG. Cell biology: Tubulin acetylation and cell motility. Nature, 2003, 421: 230.

[44] ParkS-Y, KimJ-S. A short guide to histone deacetylases including recent progress on class II enzymes. Experimental & Molecular Medicine, 2020, 52: 204-212.

[45] ParmigianiRB, et al. . HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105: 9633-9638.

[46] ParveenR, HariharD, ChatterjiBP. Recent histone deacetylase inhibitors in cancer therapy. Cancer, 2023, 129: 3372-3380.

[47] PassaroE, et al. . HDAC6 inhibition extinguishes autophagy in cancer: Recent insights. Cancers, 2021, 13: 6280.

[48] Peng, J., Liu, H., Liu, Y., Liu, J., Zhao, Q., Liu, W., Niu, H., Xue, H., Sun, J., & Wu, J. (2024). HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents. Bioorganic chemistry, 153, 107818. https://doi.org/10.1016/j.bioorg.2024.107818

[49] PietrobonoS, GagliardiS, SteccaB. Non-canonical hedgehog signaling pathway in cancer: Activation of GLI transcription factors beyond smoothened. Frontiers in Genetics, 2019, 10: 556.

[50] PolyakK, et al. . p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes & Development, 1994, 8: 9-22.

[51] PubChem. Bml-210. https://pubchem.ncbi.nlm.nih.gov/compound/9543540

[52] PulyaS, et al. . HDAC6 as privileged target in drug discovery: A perspective. Pharmacological Research, 2021, 163. 105274

[53] QiW, QiW, XiongD, LongM. Quercetin: Its antioxidant mechanism, antibacterial properties and potential application in prevention and control of toxipathy. Molecules, 2022, 27: 6545.

[54] RangannaK, SelvamC, ShivacharA, YousefipourZ. Histone deacetylase inhibitors as multitarget-directed epi-drugs in blocking PI3K oncogenic signaling: A polypharmacology approach. International Journal of Molecular Sciences., 2020, 21218198.

[55] ReedSM, QuelleDE. p53 acetylation: Regulation and consequences. Cancers, 2014, 7: 30-69.

[56] RheeSG, WooHA. Multiple functions of 2-Cys peroxiredoxins, I and II, and their regulations via post-translational modifications. Free Radical Biology and Medicine, 2020, 152: 107-115.

[57] Richter-LandsbergC, LeykJ. Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration. Acta Neuropathologica, 2013, 126: 793-807.

[58] RomoliM, et al. . Valproic acid and epilepsy: From molecular mechanisms to clinical evidences. Current Neuropharmacology, 2019, 17: 926-946.

[59] SafdarA, IsmailF. A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid. Saudi Pharmaceutical Journal, 2023, 31: 265-278.

[60] SAHA. Hello Bio https://hellobio.com/saha.html

[61] SandorV, et al. . P21-dependent G1arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. British Journal of Cancer, 2000, 83: 817-825.

[62] SaraivaNZ, OliveiraCS, GarciaJM. Histone acetylation and its role in embryonic stem cell differentiation. World Journal of Stem Cells, 2010, 2: 121.

[63] SchiedelM, RobaaD, RumpfT, SipplW, JungM. The current state of NAD⁺-dependent histone deacetylases (sirtuins) as novel therapeutic targets. Medicinal Research Reviews, 2018, 38: 147-200.

[64] SchnoorM, StradalTE, RottnerK. Cortactin: Cell functions of a multifaceted actin-binding protein. Trends in Cell Biology, 2018, 28: 79-98.

[65] ShiY, et al. . Requirement of histone deacetylase 6 for interleukin-6 induced epithelial-mesenchymal transition, proliferation, and migration of peritoneal mesothelial cells. Frontiers in Pharmacology, 2021, 12. 722638

[66] ShvedunovaM, AkhtarA. Modulation of cellular processes by histone and non-histone protein acetylation. Nature Reviews Molecular Cell Biology, 2022, 23: 329-349.

[67] SongJ. EMT or apoptosis: A decision for TGF-β. Cell Research, 2007, 17: 289-290.

[68] TakaiN, et al. . Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pacific Journal of Cancer Prevention, 2011, 12: 575-580

[69] TauntonJ, HassigCA, SchreiberSL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science, 1996, 272: 408-411.

[70] The histone methyltransferase SMYD5 plays a role in regulating plasma-cell antibody production and macrophage inflammatory cytokine secretion in vivo. ProQuest. https://www.proquest.com/openview/d746acb704cf6d8d75008331f82c63a1/1?pq-origsite=gscholar&cbl=18750&diss=y

[71] TranAThe role of HDAC6 and microtubule acetylation in the regulation of cellular motility, 2010Columbia University

[72] Trichostatin A. (2024). Wikipedia.

[73] TrugiloKP, et al. . The role of transforming growth factor β in cervical carcinogenesis. Cytokine & Growth Factor Reviews, 2024, 80: 12-23.

[74] TsujiN, KobayashiM, NagashimaK, WakisakaY, KoizumiK. A new antifungal antibiotic, trichostatin. The Journal of Antibiotics, 1976, 29: 1-6.

[75] TsujiT, NakagawaR, SugimotoN, FukuharaK. Characterization of disulfide bonds in recombinant proteins: Reduced human interleukin 2 in inclusion bodies and its oxidative refolding. Biochemistry, 1987, 26: 3129-3134.

[76] Valenzuela-FernandezA, CabreroJR, SerradorJM, Sanchez-MadridF. HDAC6: A key regulator of cytoskeleton, cell migration and cell–cell interactions. Trends in Cell Biology, 2008, 18: 291-297.

[77] Valproic acid(PIM 551). https://www.inchem.org/documents/pims/pharm/pim551.htm

[78] VembuPTemporal regulation of cytokine-mediated gene expression changes upon genetic intervention of histone deacetylase 6, 2019The George Washington University

[79] VuletićA, Mirjačić MartinovićK, SpasićJ. Role of histone deacetylase 6 and histone deacetylase 6 inhibition in colorectal cancer. Pharmaceutics, 2023, 16: 54.

[80] WangW, Tse-DinhY-C. Recent advances in use of topoisomerase inhibitors in combination cancer therapy. Current Topics in Medicinal Chemistry, 2019, 19: 730-740.

[81] Wang P, Wang Z, Liu J. (2020). Role of HDACs in normal and malignant hematopoiesis. Molecular cancer, 19, 1-21.

[82] WeiY, et al. . B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments. Oncogene, 2021, 40: 4737-4745.

[83] WośI, TabarkiewiczJ. Effect of interleukin-6, -17, -21, -22, and -23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis. Immunologic Research, 2021, 69: 26-42.

[84] XuD, LuoXM, ReillyCM. HDAC6 deletion decreases pristane-induced inflammation. ImmunoHorizons, 2024, 8: 668-678.

[85] XuR, HeX, XuJ, YuG, WuY. Immunometabolism: Signaling pathways, homeostasis, and therapeutic targets. MedComm, 2024, 5. e789

[86] YangH, et al. . Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. The FASEB Journal, 2014, 28: 4265-4279.

[87] YilmazM, ChristoforiG. Mechanisms of motility in metastasizing cells. Molecular Cancer Research, 2010, 8: 629-642.

[88] ZhangJ, et al. . Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors. Autophagy, 2018.

[89] ZhaoM, MishraL, DengC-X. The role of TGF-β/SMAD4 signaling in cancer. International Journal of Biological Sciences, 2018, 14: 111.

[90] ZhengY-C, et al. . Curriculum vitae of HDAC6 in solid tumors. International Journal of Biological Macromolecules, 2023, 230. 123219

[91] ZhuS, Goldschmidt-ClermontPJ, DongC. Transforming growth factor-β-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circulation Research, 2004, 94: 617-625.

Funding

Jilin Provincial Scientific and Technological Development Program(YDZJ202201ZYTS571)

Department of Science and Technology of Jilin Province(YDZJ202301ZYTS052)

RIGHTS & PERMISSIONS

Shenzhen University School of Medicine; Fondazione Istituto FIRC di Oncologia Molecolare